Advertisement

Diabetes Mellitus and Glucagonoma

Synopsis

  • Diabetis Mellitus
    • Diabetic dermopathy is the most common skin disease in diabetes; it is present in nearly half of diabetic patients older than 50 years. It is caused by diabetic microangiopathy, polyneuropathy and infections frequently associated with retinopathy or nephropathy. The typical lesions are flat scars ulcers and bullae mainly at the legs. Fifteen percent of individuals with diabetes develop a foot ulcer during their lifetime- a risk factor for subsequent amputations. Treatment mainly means prevention of ulcers. Correct foot care is mandatory.

    • Skin reaction to insulin therapy occur in 5-10% of patients. There are local and systemic allergic reactions including erythema, itching, urticae and infiltrated plaques, urticaria and anaphylactic shock. A special feature is lipoatrophy occurring at the injection sites. Treatment depends on the severity of the phenomena. Frequent change of injection site is advisable. Antihistamines may suppress the itching. In lipatropy, treatment with glucocorticoids has been useful.

    • Necrobiosis lipoidica diabeticorum is a slowly progressing, granulomatous disorder of unknown etiology, usually occurring on the pretibial areas. The skin is atrophic and yellowish-brown, enlarged vessels may be seen through the translucent skin. Histopathologically, large areas of necrobiosis in the dermis are seen, surrounded by infiltrates of epithelioid cells, lymphocytes and multinucleate giant cells. A great variety of regimen has been proposed. It appears that NLD is associated with poor glucose control.

    • Scleredema adultorum is associated with diabetes mellitus, but association with paraproteinemias and myeloma has also been reported. The skin is tight, thickened and hardened, involving neck, chest, shoulders, and the upper back. The patients report limitation of motion in the joints. Histopathological, the dermis is thickened, the collagen fibres appear to be swollen and separated by wide spaces (dermal fenestration). For treatment, physiotherapy as well as with antibiotics, glucocorticoids, immunosuppressants, and photopheresis were applied. Photochemotherapy appears to be the treatment of choice.

  • Glucagonoma Syndrome
    • Necrolytic migratory erythema as the skin manifestation of glucagonoma syndrome is the first symptom of glucagonoma in roughly 79% of patients, its first symptoms being macules, bullae and crusted plaques. Later the central part of the lesions heals leaving postinflammatory hyperpigmentation, giving the lesions an annular appearance. Histopathologically, the epidermis shows clefts in the upper spinous cell layer and a diffuse epidermal pallor. Treatment requires surgical exstirpation of the underlying tumour. Skin lesions then clear within a week.

Keywords

Human Insulin Insulin Lispro Insulin Detemir Tinea Pedis Acanthosis Nigricans 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abdollahi Daneshpazhooh M, Amirchaghmaghi E, Sheikhi S, Eshrati B, Bastanhagh. Dermop-athy and retinopathy in diabetes: is there an association? Dermatology. 2007;214(2):133–6.PubMedGoogle Scholar
  2. Abdul-Ghani M, Nawaf G, Nawaf F, Itzhak B, Minuchin O, Vardi P. Increased prevalence of micro-vascular complications in type 2 diabetes patients with the metabolic syndrome. Israel Med Assoc J. 2006;8(6):378–82.Google Scholar
  3. Alexander EK, Robinson M, Staniec M, Dluhy RG. Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome. Clin Endo-crinol (Oxf). 2002;57(6):827–31.CrossRefGoogle Scholar
  4. Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg. 2005;9(6):296–302.PubMedCrossRefGoogle Scholar
  5. Al-Khenaizan S, Al Thubaiti M, Al Alwan I. Lispro insulin-induced lipoatrophy: a new case. Pedi-atr Diabetes. 2007;8(6):393–6.CrossRefGoogle Scholar
  6. Amon-Herzig-Kellerer. Antidiabetica. Wissenschaftliche Verlagsgesellschaft, Stuttgart 2000.Google Scholar
  7. Arranz A, Andia V, López-Guzmán A. A case of lipoatrophy with Lispro insulin without insulin pump therapy. Diabetes Care. 2004;27(2):625–6.PubMedCrossRefGoogle Scholar
  8. Aslan E, Körber A, Grabbe S, Dissemond J. Erfolgreiche Therapie einer exulzerierten Necrobiosis lipoidica non diabeticorum mit Ciclosporin. Hautarzt. 2007;58(8):684–8.PubMedCrossRefGoogle Scholar
  9. Beers WH, Ince A, Moore TL. Scleredema adultorum of Buschke: a case report and review of the literature. Semin Arthritis Rheum. 2006;35(6):355–9.PubMedCrossRefGoogle Scholar
  10. Beltrand J, Guilmin-Crepon S, Castanet M, Peuchmaur M, Czernichow P, Levy-Marchal C. Insulin allergy and extensive lipoatrophy in child with type 1 diabetes. Horm Res. 2006;65(5):253–60.PubMedCrossRefGoogle Scholar
  11. Bewley A P, Ross JS, Bunker CB, Staughton RC. Successful treatment of a patient with octreotide-resistant necrolytic migratory erythema. Br J Dermatol. 1996;134(6):1101–4.PubMedCrossRefGoogle Scholar
  12. Blanco C, Castillo R, Quiralte J, Delgado J, Garcia I, de Pablos P, Carrillo T. Anaphylaxis to subcutaneous neutral protamine Hagedorn insulin with simultaneous sensitization to protamine and insulin. Allergy. 1996;51(6):421–4.PubMedGoogle Scholar
  13. Bodtger U, Wittrup M. A rational clinical approach to suspected insulin allergy: status after five years and 22 cases. Diabet Med. 2005;22(1):102–6.PubMedCrossRefGoogle Scholar
  14. Bowen AR, Smith L, Zone JJ. Scleredema adultorum of Buschke treated with radiation. Arch Dermatol. 2003;139(6):780–4.PubMedCrossRefGoogle Scholar
  15. Boyd AS. Treatment of necrobiosis lipoidica with pioglitazone. J Am Acad Dermatol. 2007;57 (5 Suppl):S120–1.PubMedCrossRefGoogle Scholar
  16. Brownlee M, Aiello L P, Friedman E, Vinik AI, Nesto RW, Boulton JM. Complications of diabetes mellitus, pp 1509–84. In: Williams Textbook of Endocrinology, 10th Edition, Eds: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, Saunders, Philadelphia, 2003Google Scholar
  17. Camisa C. Somatostatin and a long-acting analogue, octreotide acetate. Relevance to dermatology. Arch Dermatol. 1989;125(3):407–12.PubMedCrossRefGoogle Scholar
  18. Case CC, Vassilopoulou-Sellin R. Reproduction of features of the glucagonoma syndrome with continuous intravenous glucagon infusion as therapy for tumor-induced hypoglycemia. Endocr Pract. 2003;9(1):22–5.PubMedGoogle Scholar
  19. Castera V, Dutour-Meyer A, Koeppel M, Petitjean C, Darmon P. Systemic allergy to human insulin and its rapid and long acting analogs:successful treatment by continuous subcutaneous insulin lispro infusion. Diabet Metab. 2005;31(4 Pt 1):391–400.CrossRefGoogle Scholar
  20. Chao SC, Lee JY. Brittle nails and dyspareunia as first clues to recurrences of malignant gluca-gonoma. Br J Dermatol. 2002;146(6):1071–4.PubMedCrossRefGoogle Scholar
  21. Cohen O, Yaniv R, Karasik A, Trau H. Necrobiosis lipoidica and diabetic control revisited. Med Hypotheses. 1996;46(4):348–50.PubMedCrossRefGoogle Scholar
  22. Dahl PR, Zalla MJ, Winkelmann RK. Localized involutional lipoatrophy: a clinicopathologic study of 16 patients. J Am Acad Dermatol. 1996;35(4):523–8.PubMedCrossRefGoogle Scholar
  23. De la Torre C, Losada A, Cruces MJ. Necrobiosis lipoidica: a case with prominent cholesterol clefting and transepithelial elimination. Am J Dermatopathol. 1999;21(6):575–7.PubMedCrossRefGoogle Scholar
  24. Del Olmo MI, Campos V, Abellán P, Merino-Torres JF, Piñón F. A case of lipoatrophy with insulin detemir. Diabetes Res Clin Pract. 2008;80(1):e20–1.PubMedCrossRefGoogle Scholar
  25. Diris N, Colomb M, Leymarie F, Durlach V, Caron J, Bernard P. Dermatoses non infectieuses au cours du diabète sucré: étude prospective de 308 malades. Ann Dermatol Venereol. 2003;130(11): 1009–14.PubMedGoogle Scholar
  26. Eberlein-Konig B, Vogel M, Katzer K, Hein R, Kohn FM, Ring J, Abeck D. Successful UVA1 phototherapy in a patient with scleredema adultorum. J Eur Acad Dermatol Venereol. 2005;19(2):203–4.PubMedCrossRefGoogle Scholar
  27. Edney JA, Hofmann S, Thompson JS, Kessinger A. Glucagonoma syndrome is an underdiagnosed clinical entity. Am J Surg. 1990;160(6):625–8.PubMedCrossRefGoogle Scholar
  28. El Rassi Z, Partensky C, Valette PJ, Berger F, Chayvialle JA. Necrolytic migratory erythema, first symptom of a malignant glucagonoma: treatment by long-acting somatostatin and surgical resection. Report of three cases. Eur J Surg Oncol. 1998;24(6):562–7.PubMedCrossRefGoogle Scholar
  29. Elsborg L, Glenthoj A. Effect of somatostatin in necrolytic migratory erythema of glucagonoma. Acta Med Scand. 1985;218(2):245–9.PubMedGoogle Scholar
  30. Fineberg SE, Huang J, Brunelle R, Gulliya KS, Anderson JH Jr. Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes. Diabetes Care. 2003;26:89–96.PubMedCrossRefGoogle Scholar
  31. Foss NT, Polon D P, Takada MH, Foss-Freitas MC, Foss MC. Skin lesions in diabetic patients. Rev Saude Publica. 2005;39(4):677–82.PubMedCrossRefGoogle Scholar
  32. Franchimont C, Pierard GE, Luyckx AS, Gerard J, Lapiere CM. Angioplastic necrolytic migratory erythema. Unique association of necrolytic migratory erythema, extensive angioplasia, and high molecular weight glucagon-like polypeptide. Am J Dermatopathol. 1982;4(6):485–95.PubMedCrossRefGoogle Scholar
  33. Frykberg RG. An evidence-based approach to diabetic foot infections. Am J Surg. 2003;186(5A): 44S–54SPubMedCrossRefGoogle Scholar
  34. Gebauer K, Armstrong M. Koebner phenomenon with necrobiosis lipoidica diabeticorum. Int J Dermatol. 1993;32(12):895–6.PubMedCrossRefGoogle Scholar
  35. Greenman RL, Panasyuk S, Wang X, Lyons TE, Dinh T, Longoria L, Giurini JM, Freeman J, Khaodhiar L, Veves A. Early changes in the skin microcirculation and muscle metabolism of the diabetic foot. Lancet. 2005;366(9498):1711–7.PubMedCrossRefGoogle Scholar
  36. Gudi VS, Campbell S, Gould DJ, Marshall R. Squamous cell carcinoma in an area of necrobiosis lipoidica diabeticorum: a case report. Clin Exp Dermatol. 2000;25(8):597–9.PubMedCrossRefGoogle Scholar
  37. Haustein U F. Scleroderma and pseudo-scleroderma: uncommon presentations. Clin Dermatol. 2005;23(5):480–90.PubMedCrossRefGoogle Scholar
  38. Hunt SJ, Narus VT, Abell E. Necrolytic migratory erythema: dyskeratotic dermatitis, a clue to early diagnosis. J Am Acad Dermatol. 1991;24(3):473–7.PubMedCrossRefGoogle Scholar
  39. Hussein S F, Siddique H, Coates P, Green J. Lipoatrophy is a thing of the past, or is it? Diabet Med. 2007;24(12):1470–2.PubMedCrossRefGoogle Scholar
  40. Jacob N, Gleichmann U, Stadler R. Sclerödema adultorum Buschke bei secundärem Hyperpar-athyroidismus. Hautarzt. 2002;53(2):121–5.PubMedCrossRefGoogle Scholar
  41. Johnson SM, Smoller BR, Lamps LW, Horn TD. Necrolytic migratory erythema as the only presenting sign of a glucagonoma. J Am Acad Dermatol. 2003;49(2):325–8.PubMedCrossRefGoogle Scholar
  42. Kasper CS, McMurry K. Necrolytic migratory erythema without glucagonoma versus canine superficial necrolytic dermatitis: is hepatic impairment a clue to pathogenesis? J Am Acad Dermatol. 1991;25(3):534–41.PubMedCrossRefGoogle Scholar
  43. Katz R, Fischmann AB, Galotto J, Guccio JG, Higgins GA, Ortega LG, West WH, Recant L. Necrolytic migratory erythema, presenting as candidiasis, due to a pancreatic glucagonoma. Cancer. 1979;44(2):558–63.PubMedCrossRefGoogle Scholar
  44. Kheir SM, Omura E F, Grizzle WE, Herrera GA, Lee I. Histologic variation in the skin lesions of the glucagonoma syndrome. Am J Surg Pathol. 1986;10(7):445–53.PubMedCrossRefGoogle Scholar
  45. Kiziltan ME, Benbir G, Akalin MA. Is diabetic dermopathy a sign for severe neuropathy in patients with diabetes mellitus? Nerve conduction studies and symptom analysis. Clin Neurophysiol. 2006;117(8):1862–9.PubMedCrossRefGoogle Scholar
  46. Kovacs RK, Korom I, Dobozy A, Farkas G, Ormos J, Kemeny L. Necrolytic migratory erythema. J Cutan Pathol. 2006;33(3):242–5.PubMedCrossRefGoogle Scholar
  47. Kreuter A, Knierim C, Stücker M, Pawlak F et al. Fumaric acid esters in necrobiosis lipoidica: results of a prospective, non-controlled study. Br J Dermatol. 2005;153 (4):802–7PubMedCrossRefGoogle Scholar
  48. Lamba S, Krishtul A, Tan MH, Lebwohl MG. Acanthosis nigricans in a plaque of scleredema on the back of a diabetic patient: a case report. Int J Dermatol. 2005;44(1):45–7.PubMedCrossRefGoogle Scholar
  49. Lee AY, Chey WY, Choi J, Jeon JS. Insulin-induced drug eruptions and reliability of skin tests. Acta Derm Venereol. 2002;82(2):114–7.PubMedCrossRefGoogle Scholar
  50. Linana JJ, Montoro FJ, Hernandez MD, Basomba A. Adverse reactions to insulin. An Med Interna. 1997;14(7):369–72.PubMedGoogle Scholar
  51. Long CC, Laidler P, Holt PJ. Suprabasal acantholysis–an unusual feature of necrolytic migratory erythema. Clin Exp Dermatol. 1993;18(5):464–7.PubMedCrossRefGoogle Scholar
  52. Lopez X, Castells M, Ricker A, Velazquez EF, Mun E, Goldfine AB. Human insulin analog– induced lipoatrophy. Diabetes Care. 2008;31(3):442–4.PubMedCrossRefGoogle Scholar
  53. Mallinson CN, Bloom SR, Warin AP, Salmon PR, Cox B. A glucagonoma syndrome. Lancet. 1974;2(7871):1–5.PubMedCrossRefGoogle Scholar
  54. Marinkovich M P, Botella R, Datloff J, Sangueza O P. Necrolytic migratory erythema without gluca-gonoma in patients with liver disease. J Am Acad Dermatol. 1995;32(4):604–9.PubMedCrossRefGoogle Scholar
  55. McFadden N, Ree K, Søyland E, Larsen TE. Scleredema adultorum associated with a monoclonal gammopathy and generalized hyperpigmentation. Arch Dermatol. 1987;123(5):629–32.PubMedCrossRefGoogle Scholar
  56. McIntosh BC, Lahinjani S, Narayan D. Necrobiosis lipoidica resulting in squamous cell carcinoma. Conn Med. 2005;69(7):401–3.PubMedGoogle Scholar
  57. Mendonca DA, Cosker T, Makwana NK. Vacuum-assisted closure to aid wound healing in foot and ankle surgery. Foot Ankle Int. 2005;26(9):761–6.PubMedGoogle Scholar
  58. Mullans EA, Cohen PR. Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-associated necrolytic migratory erythema. J Am Acad Dermatol. 1998;38 (5 Pt 2):866–73.PubMedCrossRefGoogle Scholar
  59. Ngo BT, Hayes KD, DiMiao DJ, Srinivasan SK, Huerter CJ, Rendell MS. Manifestations of cutaneous diabetic microangiopathy. Am J Clin Dermatol. 2005;6(4):225–37.PubMedCrossRefGoogle Scholar
  60. Nguyen K, Washenik K, Shupack J. Necrobiosis lipoidica diabeticorum treated with chloroquine. J Am Acad Dermatol. 2002;46(2 Suppl Case Reports):S34–6.PubMedCrossRefGoogle Scholar
  61. Ossowski B, Baum C. Das Pseudoglucagonom-Syndrome. Hautarzt. 1995;46(3):173–6.PubMedCrossRefGoogle Scholar
  62. Parmar RC, Bavdekar SB, Bansal S, Doraiswamy A, Khambadkone S. Scleredema adultorum. J Postgrad Med. 2000;46(2):91–3.PubMedGoogle Scholar
  63. Perniciaro C, Rappaport KD, White JW Jr. Apoptosis with positive direct immunofluorescence findings in a patient with necrolytic migratory erythema. Cutis. 1998;62(3):129–32.PubMedGoogle Scholar
  64. Pinzur M, Freeland R, Juknelis D. The association between body mass index and foot disorders in diabetic patients. Foot Ankle Int. 2005;26(5):375–7.PubMedGoogle Scholar
  65. Radermecker R P, Piérard GE, Scheen AJ. Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs. Am J Clin Dermatol. 2007;8(1):21–8.PubMedCrossRefGoogle Scholar
  66. Raile K, Noelle V, Landgraf R, Schwarz H P. Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes. Exp Clin Endocri-nol Diabet. 2001;109(8):393–6.CrossRefGoogle Scholar
  67. Rallis E, Korfitis C, Gregoriou S, Rigopoulos D. Assigning new roles to topical tacrolimus. Expert Opin Investig Drugs. 2007;16(8):1267–76.PubMedCrossRefGoogle Scholar
  68. Ramos AJ, Farias MA. Human insulin-induced lipoatrophy: a successful treatment with glucocor-ticoid. Diabetes Care. 2006;29(4):926–7.PubMedCrossRefGoogle Scholar
  69. Rappersberger K, Wolff-Schreiner E, Konrad K, Wolff K. Das Glucagonom-Syndrom. Hautarzt. 1987;38(10):589–98.PubMedGoogle Scholar
  70. Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol. 2003;4(10):661–7.PubMedCrossRefGoogle Scholar
  71. Robbins JM. Treatment of onychomycosis in the diabetic patient population. J Diabetes Complications. 2003;17(2):98–104.PubMedCrossRefGoogle Scholar
  72. Romano G, Moretti G, Di Benedetto A, Giofre C, Di Cesare E, Russo G, Califano L, Cucinotta D. Skin lesions in diabetes mellitus: prevalence and clinical correlations. Diabetes Res Clin Pract. 1998;39(2):101–6.PubMedCrossRefGoogle Scholar
  73. Shemer A, Bergman R, Linn S, Kantor Y, Friedman-Birnbaum R. Diabetic dermopathy and internal complications in diabetes mellitus. Int J Dermatol. 1998;37(2):113–5.PubMedCrossRefGoogle Scholar
  74. Shimizu I, Furuya K, Osawa H, Fujii Y, Makino H. 10a-65: a case of insulin-induced localized lobular panniculitis with evidence for the phagocytosis of insulin by histiocytes. Endocr J. 2007;54(3):477–80.PubMedCrossRefGoogle Scholar
  75. Smith A P, Doolas A, Staren ED. Rapid resolution of necrolytic migratory erythema after gluca-gonoma resection. J Surg Oncol. 1996;61(4):306–9.PubMedCrossRefGoogle Scholar
  76. Tanner M, Brasch J, Christophers E. Erythema necroticans migrans ohne Glucagonom. Hautarzt. 1994;45(7):480–3.PubMedCrossRefGoogle Scholar
  77. Technau K, Renkl A, Norgauer J, Ziemer M. Necrolytic migratory erythema with myelodysplastic syndrome without glucagonoma. Eur J Dermatol. 2005;15(2):110–2.PubMedGoogle Scholar
  78. Tierney E P, Badger J. Etiology and pathogenesis of necrolytic migratory erythema: review of the literature. MedGenMed. 2004;6(3):4.PubMedGoogle Scholar
  79. Tokura Y, Mizushima Y, Hata M, Takigawa M. Necrobiosis lipoidica of the glans penis. J Am Acad Dermatol. 2003;49(5):921–4.PubMedCrossRefGoogle Scholar
  80. Tom WL, Peng DH, Allaei A, Hsu D, Hata TR. The effect of short-contact topical tretinoin therapy for foot ulcers in patients with diabetes. Arch Dermatol. 2005;141(11):1373–7.PubMedCrossRefGoogle Scholar
  81. Truhan A P, Roenigk Jr. HH. The cutaneous mucinoses. J Am Acad Dermatol. 1986;14(1):1–18.PubMedCrossRefGoogle Scholar
  82. Tuchinda C, Kerr HA, Taylor CR, Jacobe H, Bergamo BM, Elmets C, Rivard J, Lim HW. UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States. Photoder-matol Photoimmunol Photomed. 2006;22(5):247–53.PubMedCrossRefGoogle Scholar
  83. van Beek A P, de Haas ER, van Vloten WA, Lips CJ, Roijers JF, Canninga-van Dijk MR. The glu-cagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol. 2004;151(5):531–7.PubMedCrossRefGoogle Scholar
  84. Venencie PY, Powell FC, Su W P, Perry HO. Scleredema: a review of thirty-three cases. J Am Acad Dermatol. 1984;11(1):128–34.PubMedCrossRefGoogle Scholar
  85. Vijayasingam SM, Thai AC, Chan HL. Non-infective skin associations of diabetes mellitus. Ann Acad Med Singapore. 1988;17(4):526–35.PubMedGoogle Scholar
  86. Wee SA, Possick P. Necrobiosis lipoidica. Dermatol Online J. 2004;10(3):18.PubMedGoogle Scholar
  87. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine (Baltimore). 1996;75(2):53–63.CrossRefGoogle Scholar
  88. Wigington G, Ngo B, Rendell M. Skin blood flow in diabetic dermopathy. Arch Dermatol. 2004;140(10):1248–50.PubMedCrossRefGoogle Scholar
  89. Wonders J, Eekhoff EM, Heine R, Bruynzeel D P, Rustemeyer T. Insulin allergy: background, diagnosis and treatment. Ned Tijdschr Geneeskd. 2005;149(50):2783–8.PubMedGoogle Scholar
  90. Yokoyama H, Fukumoto S, Koyama H, Emoto M, Kitagawa Y, Nishizawa Y. Insulin allergy; desensiti-zation with crystalline zinc-insulin and steroid tapering. Diabetes Res Clin Pract. 2003;61(3): 161–6.PubMedCrossRefGoogle Scholar
  91. Yosipovitch G, Hodak E, Vardi P, Shraga I, Karp M, Sprecher E, David M. The prevalence of cutaneous manifestations in IDDM patients and their association with diabetes risk factors and microvascular complications. Diabetes Care. 1998;21(4):506–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Personalised recommendations